PHILADELPHIA, Feb. 11 /PRNewswire/ — Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) announced that results published today in a leading medical journal show a new one-step diagnostic test for Chronic Fatigue Syndrome (CFS) in European programs has accurately identified this debilitating condition in patients, which may thereby accelerate the overall process of effective therapeutic intervention.
The breakthrough results, published in the peer-reviewed medical journal, “American Journal of Medicine,” are part of a study by leading researchers in France and Belgium who are members of the Scientific Advisory Committee for Hemispherx Europe. The researchers evaluated more than 100 patients with different disorders under “blinded conditions” and found that a new biological marker, which was targeted to CFS, was not evident in patients with other fatiguing conditions such as fibromyalgia or depression.
CFS is a chronic debilitating condition characterized by disabling fatigue, fever, myalgia and neurocognitive disturbances. Because a new diagnostic test can identify CFS in patients, therapeutic intervention can take place much more quickly. In fact, certain patients in this study who were diagnosed with CFS using this new test received Ampligen(R), a new product for which Hemispherx Europe has pending marketing applications in 15 European countries.
In related developments, Hemispherx said that the European Parliament recently passed new laws which will accelerate the availability of specific treatments for CFS, and EU member nations, including Italy and Belgium, are actively taking new official regulatory steps to facilitate reimbursement of new medications, which may potentially interrupt the natural history and devastating societal impact of untreated CFS.
Hemispherx Biopharma, which is based in Philadelphia, is a pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including CFS, HIV and hepatitis. Its flagship products are Ampligen(R), which is being developed for CFS and drug-resistant HIV, and polyadenur, which is being developed for hepatitis B and C.
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company’s filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements.
Contact: William A. Carter, M.D., CEO & Chairman of Hemispherx Biopharma, Inc., 215-988-0080; or Mark Kollar of Broadgate Consultants, 212-232-2222, fax, 212-232-3232; or Dianne Will, Investor Relations, 214-954-9300, fax, 214-954-9333